MacroGenics CEO to Present at H.C. Wainwright Conference
Event summary
- MacroGenics CEO Eric Risser to present at H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, at 9:30 a.m. ET.
- Webcast available on MacroGenics' Investor Relations website, archived for 30 days.
- MacroGenics focuses on developing antibody-based therapeutics for cancer treatment.
The big picture
MacroGenics' participation in the H.C. Wainwright conference underscores its focus on investor engagement amid a competitive biopharmaceutical landscape. The company's emphasis on antibody-based cancer treatments aligns with broader industry trends toward targeted therapies. The presentation provides a platform to showcase its technological platforms and potential for revenue growth through strategic collaborations.
What we're watching
- Pipeline Progress
- How MacroGenics' presentation will highlight advancements in its antibody-based therapeutics pipeline.
- Investor Sentiment
- Whether the conference presentation will influence investor confidence in MacroGenics' strategic direction.
- Collaborative Opportunities
- The pace at which MacroGenics can secure new strategic collaborations with global pharmaceutical companies.
Related topics